CH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer's disease

Zehui Liu; Wanyan Wang; Tingyu Huang; Cunfang Wang; Ying Huang; Yong Tang; Jin Huang

doi:10.1371/journal.pone.0222757

CH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer's disease

PLoS One. 2019 Sep 23;14(9):e0222757. doi: 10.1371/journal.pone.0222757. eCollection 2019.

Authors

Zehui Liu¹, Wanyan Wang¹, Tingyu Huang², Cunfang Wang², Ying Huang³, Yong Tang⁴, Jin Huang¹

Affiliations

¹ State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
² Guangdong Long Fu Pharmaceutical Co., Ltd, Guangdong, China.
³ Guangdong Institute for Drug Control, Guangdong, China.
⁴ Department of Urology, Wuming Hospital of Guangxi Medical University, Guangxi, China.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder, and is the most common type of cognitive impairment and dementia. There is a pressing need to improve the clinical efficacy and quality of life for AD patients, as limited treatments options for AD patients have been developed until now. In this study, we aim to investigate the protective effect of CH(II), a cerebroprotein hydrolysate consisted of abundant biological peptides, on preclinical model of AD. We found that CH(II) treatment effectively protects oxygen glucose deprivation (OGD)-induced N2A cell viability impairment and cell apoptosis. In addition, CH(II) significantly reduces H2O2-induced ROS accumulation and exhibits the protective activities against H2O2-induced oxidative injury. Intriguingly, we found that CH(II) treatment can effectively promote neurite outgrowth of N2A cells. Moreover, CH(II) obviously improve the cognitive and memorial function in scopolamine-induced amnesia mice model. Taken together, this study provides evidences of the neuroprotective activities of CH(II) and offers a potential therapeutic strategy for AD patients.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Alzheimer Disease / physiopathology*
Animals
Apoptosis / drug effects
Cell Line, Tumor
Cell Survival / drug effects
Cognition / drug effects*
Cognition / physiology
Disease Models, Animal*
Female
Glucose / metabolism
Glucose / pharmacology
Hydrogen Peroxide / pharmacology
Intracellular Space / drug effects*
Intracellular Space / metabolism
Mice, Inbred C57BL
Neurogenesis / drug effects
Neuroprotective Agents / pharmacology*
Oxidants / pharmacology
Oxygen / metabolism
Oxygen / pharmacology
Reactive Oxygen Species / metabolism*

Substances

Neuroprotective Agents
Oxidants
Reactive Oxygen Species
Hydrogen Peroxide
Glucose
Oxygen

Grants and funding

This study was supported by the National Natural Science Foundation of China (81773775), Open Funding Project of the State Key Laboratory of Bioreactor Engineering, State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Guangxi Normal University, CMEMR2017-B01). The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.